

Special Issue

Hepatitis E Virus and Immunology Research

Message from the Guest Editor

HEV is the most common cause of acute viral hepatitis worldwide. Improvements in diagnostic algorithms based on serological and molecular tools are associated with a dramatic increase in the number of cases of HEV infection reported to public health authorities. HEV can take different transmission routes depending on the genotype. HEV-1 and HEV-2 are predominant in countries with limited resources, where they are transmitted via contaminated water, while HEV-3 and HEV-4 are predominant in the other countries, where they are transmitted from a large animal reservoir, mainly pigs. HEV-1 can result in fulminant hepatic failure and severe placental disease in pregnant women. We now know that only HEV-3 and HEV-4 can produce chronic hepatitis E in immunocompromised individuals. Furthermore, extra-hepatic manifestations such as neurological and renal manifestations are increasingly being reported. The mechanisms responsible for the variety of clinical manifestations of HEV infection remain poorly characterized. This Special Issue of *Vaccines* is dedicated to our current knowledge of HEV and future directions of research on HEV vaccines.

Guest Editor

Prof. Dr. Jacques Izopet

Laboratory of Virology – Federative Institute of Biology, Toulouse University Hospital & INSERM U1043/CNRS5282, Toulouse, France

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/68798

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).